Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective Study from a Single Center in Kosovo

Edmond Komoni; Fisnik Jashari; Dren Boshnjaku; Blerim Myftiu; Melihate Pushka; Afrim Blyta; Rajmonda Nallbani-Komoni

doi:10.12659/MSM.942992

30 January 2024: Clinical Research

Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective Study from a Single Center in Kosovo

Edmond Komoni ^1ABCDEFG , Fisnik Jashari ^1ACD , Dren Boshnjaku ^1DF , Blerim Myftiu ^2BF , Melihate Pushka ^1BF , Afrim Blyta ^1A , Rajmonda Nallbani-Komoni ^3ACEF*

DOI: 10.12659/MSM.942992

Med Sci Monit 2024; 30:e942992

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Figure 1 Severity of COVID-19 symptoms in patients with MS. (A) Patients categorized based on the type of MS; (B) Patients categorized based on DMTs. DMT – disease-modifying therapy; MS – multiple sclerosis. RRMS – relapsing-remitting MS; SPMS – second primary MS; PPMS – primary progressive MS.

Back to the Article

Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective Study from a Single Center in Kosovo

Your Privacy